AI-Enabled Drug Discovery and Clinical Trials Market Size, Share, By Offering (Software Solutions and Services), Therapeutic Area (Oncology, Cardiovascular Diseases, Nervous System Diseases, Respiratory Diseases, Infectious Diseases, and Others), Application (Data Aggregation and Analysis, Clinical Trials, Drug Design, Drug Characterization, and Biomarker Research), End-User (Biopharmaceutical Industry, Contract Research Organizations (CROs), Academic and Research Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

Report Code: PMI429620 | Publish Date: March 2024 | No. of Pages: 168

Global AI Enabled Drug Discovery And Clinical Trials Market Companies

  • Accutar Biotechnology Inc.
  • Atomwise Inc.
  • Recursion
  • Insilico Medicine
  • Pfizer Inc.
  • BenevolentAI
  • Ardigen
  • AiCure
  • Biovista
  • BPT Analytics LTD
  • Lindus Health Limited
  • IQVIA
  • ReviveMed Inc.
  • Saama

Recent News:

  • Exscientia plc, announced that it would be expanding its work with Amazon Web Services (AWS) to use the cloud provider’s artificial intelligence (AI) and machine learning (ML) services to power its platform for end-to-end drug discovery and automation that aim to better target specific diseases and patients, with the goal of accelerating early drug development at a lower cost, in July 2023.
  • Accenture announced that it had made a strategic investment, through Accenture Ventures, in QuantHealth, an AI-powered clinical trial design company that simulated clinical trials in the cloud, and predicted trial outcomes with significant accuracy allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients, in January 2024.

AI-Enabled Drug Discovery and Clinical Trials Market Companies Forecast 2025-2035